

Tele No.011-23236965

Fax.No.011-23236973

**F. No. ND/CT/24/000010**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**(New Drugs Division)**

FDA Bhawan, Kotla Road,  
New Delhi-11 0002

To  
M/s Themis Medicare Ltd,  
11/12, Udyog Nagar, S.V. Road Goregaon West,  
Mumbai (India) – 400104

**Subject: Permission to conduct Phase-IV Clinical Trial of Inosine Pranobex 500mg/1000mg Tablets titled “A Phase IV, Prospective, Multi-centre, Open label, Randomized Two-Arm Study to Assess the Safety, Tolerability and Efficacy of Inosine Pranobex 500 and 1000 mg Tablets Manufactured by Themis Medicare Ltd in Patients with Influenza and Other Acute Respiratory Viral Infections” vide Protocol Number TML/IAD/05, Version 01, Dated 06 October 2023-regarding.**

Sir,

With reference to your application no.**ND/CT04/FF/2024/41810** dated **23.02.2024**; please find enclosed herewith the permission in **Form CT-06, vide No. CT/ND/21/2024** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

**Yours faithfully**

**RAJEEV SINGH**  
**RAGHUVANSHI**  
**(Dr. Rajeev Singh Raghuvanshi)**  
**Drugs Controller General (India)**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION,  
ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION,  
2.5.4.20=42d718901c99819b55263a473d025f9d11b680a911087734804  
0043ee361b, postalCode=110002, st=Delhi,  
serialNumber=657f5e47d940985d8f03bdc902d0e1fe73c1a12a1a126ea94f  
a5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.11.22 16:40:17 +05'30'

**Conditions of permission**

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the

Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

**FORM CT-06***(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Themis Medicare Ltd., 11/12, Udyog Nagar, S.V. Road Goregaon West , Mumbai (India)-400104, Telephone: 22-67607080, Fax: 22-28747198, E-Mail: api@themismedicare.com**, to conduct clinical trial of the new drug as per **Protocol no. TML/IAD/05, Version 01, Dated 06 October 2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

<b>Names of the new drug or investigational new drug:</b>	<b>Inosine Pranobex 500mg/1000 mg Tablets</b>
<b>Therapeutic class:</b>	<b>Antiviral</b>
<b>Dosage form:</b>	Tablets
<b>Composition:</b>	1) Each uncoated Tablet Contains: Inosine Pranobex..... 500mg Excipients .....Q.S.  Each uncoated Tablet Contains: Inosine Pranobex..... 1000mg Excipients .....Q.S.
<b>Indications:</b>	1) As add-on therapy for treatment of Mild Covid-19 patients with Co-Morbidities and Moderate Covid-19 patients. 2) Mucocutaneous infection due to herpes simplex virus (type 1 and/ or type II), Genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, Subacute Sclerosingpanencephalitis, influenza and other acute respiratory viral infection.
<b>Details of clinical trial sites-</b>	
<b>Sr. No.</b>	<b>Name of Principal Investigator &amp; Trial Sites</b>
<b>Ethics Committee Name/ Registration Number</b>	
1.	Dr. Dilip Namdev Kadam (Consultant Physician) Care Multispecialty Hospital Kotle Arcade, Pune Nagar Road, Wagholi, Pune - 412207, Maharashtra, India
	Care Multispecialty Hospital -Institutional Ethics Committee Kotle Arcade, Pune - Nagar Road, Wagholi, Pune — 412207, Maharashtra, India EC Registration No.: ECM/1662/Inst/MH/2022
2.	Dr. Nutan Kumar Agrawal (Professor and Head of Department) Maharani Laxmi Bai Medical College, Department of Medicine, MLB Medical College.
	Ethics Committee - M.L.B Medical College MLB Medical College & Associated Hospital MLB Medical College, Kanpur Road, Jhansi — 284128, Uttar Pradesh, India

	Kanpur Road, Jhansi - 284128, Uttar Pradesh, India	EC Registration No.: ECR/1393/Inst/UP/2020
3.	Dr. Suresh Raparthy (Senior Consultant) St. Ann's General & Cancer Hospital Kazipet, Warangal 506004, Telangana, India	St. Ann's Institutional Ethics Committee (SAIEC) St Ann's General and Cancer Hospital, Kazipet, Warangal - 506004, Telangana, India EC Registration No.: ECR/297/Inst/TG/2019
4.	Dr. Adrasetty Gopal Rao (General Physician) Medigene Multi Speciality Hospital Private limited (Akshaya Hospital), D. No, 43-9-201, Sy No. 321-323, Railway New Colony. Visakhapatnam - 530016, Andhra Pradesh, India	Institutional Ethics Committee Medigene, Multi Speciality Hospital Private Limited, Medigene Multi Speciality Hospital Private Limited, D.No,43-9-201, Sy No. 321-323, Railway New Colony. Visakhapatnam — 530016, Andhra Pradesh, India EC Registration No.: ECM 1965/Inst/AP/2024
5.	Dr, Biswaroop Mukherjee Kasturi Das Memorial Super Speciality Hospital A Unit of Dishari Health Point Pvt. Ltd., Holding No, - B1-38111New Santoshpur, Block-B, Road Bye Lane - 1, P.O. Santoshpur (M), P.S. - Maheshtala, Kolkata — 700142, West Bengal, India	Institutional Ethics committee Kasturi Das Memorial Super Speciality Hospital Institutional Ethics committee Holding No. B1-38/1/New Santoshpur, Block-B, Road Bye Lane-1,PO Santoshpur, Maheshtala, Kolkata -700142, West Bengal, India EC Registration No.: ECR/1684/Inst/B/2022

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

New Delhi

**RAJEEV SINGH**  
**RAGHUVANSHI**  
(Dr. Rajeev Singh Raghuvanshi)  
Central Licensing Authority  
Stamp

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION,  
2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f0877348040da3ee361b, postalCode=110002, st=Delhi,  
serialNumber=6575e47d940985d8f03bd902d0e1fe73cfa12a1a126e994fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.11.12 16:40:44 +05'30'